摘要
人附睾蛋白4(human epididymis 4,HE4)是近年来新发现的肿瘤标志物。卵巢癌风险评估(risk of ovarian malignancy algorithm,ROMA)模型通过计算HE4和CA125的联合指数,对于卵巢癌的诊断有较高参考价值。目前血清HE4水平作为卵巢癌诊断、疗效评估及预后判断的新指标已经逐渐应用于临床。亦有研究显示HE4在肺癌患者血清和恶性胸腔积液患者胸水中呈现较高水平表达,提示其在肺癌诊断、预后评估方面的良好作用。本文就HE4在卵巢癌及肺癌的研究现状作一综述,以系统展示HE4的生物学诊断价值。
The human epididymis protein 4（HE4） is a novel tumor marker which was discovered in recent years.Risk of ovarian malignancy algorithm（ROMA） model by calculating the combination index of HE4 and CA125,has a high reference value for the diagnosis of ovarian cancer.At present,serum HE4 level as a new indicator for the diagnosis,therapeutic evaluation,and prognosis of ovarian cancer has been applied to the clinic gradually.The existing research shows serum HE4 of patients with lung cancer and HE4 in pleural effusion of patients with malignant pleural effusion presented higher levels of expression,suggesting a promising potential in the diagnosis and the prognosis evaluation of lung cancer.In this paper,the research status of HE4 in ovarian cancer and lung cancer will be reviewed to show its value in the diagnosis of HE4 systematically.
出处
《分子诊断与治疗杂志》
2016年第5期356-360,共5页
Journal of Molecular Diagnostics and Therapy
基金
内蒙古自治区自然科学基金(2014MS0854)
关键词
HE4
卵巢癌
肺癌
恶性胸腔积液
HE4
Ovarian cancer
Lung cancer
Malignant pleural effusion
